>　部門紹介　>　主な研究実績　>　2026年


2026年

◆発表論文(英文)

1. Sustained HIF activation in adult cardiomyocytes show transient beneficial effect in murine HFpEF model.

Sugimoto H, Ono K, Chuluun-Erdene A, Pham TT, Tanaka R, Kawakami T, Ito M, Minatsuki S, Higashikuni Y, Asagiri M, Manabe I, Kohro T, Kuchimaru T, Imai Y, Takeda N.

Eur Heart J Open. 2026 Jan 22;6(1).

 

2. Efficacy of dapagliflozin on uric acid in patients with moderate-to-severe chronic kidney disease. 

Yanai K, Hirai K, Kitano T, Miyazawa H, Ito K, Ookawara S, Morishita Y.

Clin Exp Nephrol. 2026 Jan;30(1):75-86.

 

3. Effects of one-year intradialytic exercise with ergometer on body composition, physical activity and dialysis adequacy: a pilot study.

Ono K, Masuda T, Akiyama Y, Matsuoka R, Akimoto T,  Nagata D.

Discov Med. 2026 Feb;21(3).

 

4. SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial. 

Masuda T, Asakura-Kinoshita M, Oka K, Ohara K, Sakai M, Miura M, Misawa K, Hirai K, Morinari M, Akimoto T, Shimada K, Nagata D, Morishita Y.

Hypertens Res. 2026 Feb;49(2):499-507.

 

5. Establishment of immortalized murine cardiac fibroblasts for visualizing cytosolic ATP dynamics with a genetically encoded optical indicator.

Chuluun-Erdene A, Kuchimaru T, Isagawa T, Sato T, Sugimoto H, Ono K, Sawaki D, Sato S, Yamamoto M, Takeda N.

Biochem Biophys Res Commun. 2026 Mar 19;805.

 

6. Why are SGLT2 inhibitors effective in HFpEF? Implications for interstitial fluid retention and cardio-renal interaction.

Masuda T, Kariro K, Morishita Y.

Hypertens Res. 2026 Mar;49(3):724-733.

 

7.  Sodium-glucose Co-transporter 2 (SGLT2) inhibitor dapagliflozin acutely activates cardiomyocyte HIF-1α signaling via succinate, a signaling metabolite.

Sato T, Isagawa T, Sugiura Y, Sawaki D, Nakagama Y, Kuchimaru T, Minatsuki S, Sato S, Ono K, Chuluun-Erdene A, Semba H, Ito M, Kawakami T, Tanaka R, Sakamoto M, Asagiri M, Harada H, Stockmann C, Yonezawa T, Hirota Y, Kido Y, Otsu K, Kohro T, Manabe I, Komuro I, Takeda N.

J Pharmacol Sci. 2026 Apr;160(4):221-231.

主な研究実績